“`html
Recursion Pharmaceuticals Stock Gains Momentum Amid Analyst Upgrade and Insider Trading
Table of Contents
Investor interest is building around Recursion Pharmaceuticals, fueled by a recent analyst upgrade and a flurry of activity in the company’s stock among its own executives.
- A major financial institution recently upgraded Recursion Pharmaceuticals, raising its price target.
- Insiders have engaged in 14 sales of RXRX stock over the past six months, with no purchases reported.
- Recursion Pharmaceuticals reported $5.2 million in revenue for Q3 2025, an 80.16% decrease year-over-year.
- Institutional investors have been both adding to and decreasing thier positions in the stock.
Recursion Pharmaceuticals is attracting attention on the market, with a recent upgrade from a prominent financial institution sparking optimism among investors. The upgrade highlighted a raised price target and positive outlook for the company’s leading drug candidate, suggesting potential for significant results from ongoing clinical trials. This has led to renewed interest in the stock’s future performance.
Clinical Trial Data Fuels Optimism
Adding to the positive sentiment, the release of encouraging data from the TUPELO trial has generated excitement among those following recursion Pharmaceuticals. Many are hopeful that this data represents a turning point for the company after a challenging year, and are eagerly anticipating further updates.
Insider Selling Activity
over the past six months, insiders at Recursion Pharmaceuticals have been actively selling shares of their stock. A total of 14 sales have been reported, with no insider purchases during this period. This activity raises questions about the insiders’ confidence in the company’s short-term prospects.
- CEO Chris Gibson sold 1,000,000 shares for an estimated $4,850,000 on December 15, 2025.
- CFO Blake Coleman sold 500,000 shares for an estimated $2,425,000 on november 20, 2025.
- Chief Scientific Officer Jeff Sturmi sold 250,000 shares for an estimated $1,212,500 on October 10, 2025.
- Other insiders have also participated in sales, contributing to the overall trend.
Institutional investor Activity
Institutional investors have displayed a mixed sentiment towards recursion Pharmaceuticals in Q3 2025, with some increasing their holdings while others reduced their positions.
- Vanguard Group, inc.added 4,488,663 shares (+14.1%) to their portfolio in Q3 2025, for an estimated $18,099,798.
- BlackRock, Inc. added 3,368,702 shares (+11.9%) to their portfolio in Q3 2025, for an estimated $16,439,265.
- FMR LLC removed 2,356,001 shares (-42.2%) from their portfolio in Q3 2025, for an estimated $11,497,284.
- Susquehanna International Group, LLP added 2,183,837 shares (+68.1%) to their portfolio in Q3 2025, for an estimated $10,657,124.
- Geode Capital Management, LLC added 1,847,149 shares (+23.8%) to their portfolio in Q3 2025, for an estimated $9,014,087.
Analyst Ratings and Price Targets
Wall Street analysts have recently issued reports on Recursion Pharmaceuticals. Currently, two firms have issued “buy” ratings on the stock, while none have issued “sell” ratings.
- JP Morgan issued an “Overweight” rating on December 17, 2025.
- Needham issued a “Buy” rating on September 11,2025.
Analysts have established price targets for $RXRX in recent months. Three analysts have offered targets in the last six months, with a median target
